HBx-induced MiR-1269b in NF-ΚB dependent manner upregulates cell division cycle 40 homolog (CDC40) to promote proliferation and migration in hepatoma cells

Journal of Translational Medicine

Volumn 14, Issue 1, 2016, Pages

  Kong, Xiao xiao ^a   Lv, Yan ru ^a,b   Shao, Li ping ^a   Nong, Xiang yang ^a,b   Zhang, Guang ling ^c   Zhang, Yi ^a   Fan, Hong xia ^a   Liu, Min ^a   Li, Xin ^a   Tang, Hua ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b PEOPLE'S HOSPITAL OF GUANGXI ZHUANG AUTONOMOUS REGION   (China)

^c NORTH CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

CDC40; HBx; HCC; MiR 1269b; NF B

Indexed keywords

CELL CYCLE PROTEIN; CELL DIVISION CYCLE 40 HOMOLOG; HEPATITIS B VIRUS X PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MICRORNA 1269B; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; CDC40 PROTEIN, HUMAN; MIRN1269 MICRORNA, HUMAN; PROTEIN BINDING; RNA SPLICING FACTOR; TRANSACTIVATOR PROTEIN;

3' UNTRANSLATED REGION; ARTICLE; CELL CYCLE PROGRESSION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HEPATITIS B VIRUS; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NONHUMAN; NUCLEOCYTOPLASMIC TRANSPORT; PHENOTYPE; PROMOTER REGION; PROTEIN TRANSPORT; TRANSCRIPTION REGULATION; TUMOR PROMOTION; UPREGULATION; CELL CYCLE; CELL MOTION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HEP-G2 CELL LINE; LIVER TUMOR; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL CYCLE PROTEINS; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICRORNAS; NF-KAPPA B; PHENOTYPE; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA SPLICING FACTORS; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84976384017     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-016-0949-y     Document Type: Article

References (33)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374-403.
2. European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-43.
3. Su Q, Schroder CH, Hofmann WJ, Otto G, Pichlmayr R, Bannasch P. Expression of hepatitis B virus X protein in HBV-infected human livers and hepatocellular carcinomas. Hepatology. 1998;27:1109-20.
4. Zhang X, Zhang H, Ye L. Effects of hepatitis B virus X protein on the development of liver cancer. J Lab Clin Med. 2006;147:58-66.
5. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev. 2000;64:51-68.
6. Kew MC. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26(Suppl 1):144-52.
7. Kim YJ, Jung JK, Lee SY, Jang KL. Hepatitis B virus X protein overcomes stress-induced premature senescence by repressing p16(INK4a) expression via DNA methylation. Cancer Lett. 2010;288:226-35.
8. Zhang X, Liu S, Hu T, Liu S, He Y, Sun S. Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology. 2009;50:490-9.
9. Elmore LW, Hancock AR, Chang SF, Wang XW, Chang S, Callahan CP, Geller DA, Will H, Harris CC. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci USA. 1997;94:14707-12.
10. Lin Y, Nomura T, Yamashita T, Dorjsuren D, Tang H, Murakami S. The transactivation and p53-interacting functions of hepatitis B virus X protein are mutually interfering but distinct. Cancer Res. 1997;57:5137-42.
11. Choi BH, Park GT, Rho HM. Interaction of hepatitis B viral X protein and CCAAT/enhancer-binding protein alpha synergistically activates the hepatitis B viral enhancer II/pregenomic promoter. J Biol Chem. 1999;274:2858-65.
12. Tanaka Y, Kanai F, Ichimura T, Tateishi K, Asaoka Y, Guleng B, Jazag A, Ohta M, Imamura J, Ikenoue T, et al. The hepatitis B virus X protein enhances AP-1 activation through interaction with Jab1. Oncogene. 2006;25:633-42.
13. Seto E, Mitchell PJ, Yen TS. Transactivation by the hepatitis B virus X protein depends on AP-2 and other transcription factors. Nature. 1990;344:72-4.
14. Waris G, Huh KW, Siddiqui A. Mitochondrially associated hepatitis B virus X protein constitutively activates transcription factors STAT-3 and NF-ΚB via oxidative stress. Mol Cell Biol. 2001;21:7721-30.
15. Su F, Schneider RJ. Hepatitis B virus HBx protein activates transcription factor NF-kappaB by acting on multiple cytoplasmic inhibitors of rel-related proteins. J Virol. 1996;70:4558-66.
16. Weil R, Sirma H, Giannini C, Kremsdorf D, Bessia C, Dargemont C, Brechot C, Israel A. Direct association and nuclear import of the hepatitis B virus X protein with the NF-ΚB inhibitor IΚBα. Mol Cell Biol. 1999;19:6345-54.
17. Chen FE, Ghosh G. Regulation of DNA binding by Rel/NF-ΚB transcription factors: structural views. Oncogene. 1999;18:6845-52.
18. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science. 2007;318:1931-4.
19. Callegari E, Gramantieri L, Domenicali M, D'Abundo L, Sabbioni S, Negrini M. MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. Cell Death Differ. 2015;22:46-57.
20. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA. 2007;104:15805-10.
21. Yang XW, Shen GZ, Cao LQ, Jiang XF, Peng HP, Shen G, Chen D, Xue P. MicroRNA-1269 promotes proliferation in human hepatocellular carcinoma via downregulation of FOXO1. BMC Cancer. 2014;14:909.
22. Gan TQ, Tang RX, He RQ, Dang YW, Xie Y, Chen G. Upregulated MiR-1269 in hepatocellular carcinoma and its clinical significance. Int J Clin Exp Med. 2015;8:714-21.
23. Ben-Yehuda S, Russell CS, Dix I, Beggs JD, Kupiec M. Extensive genetic interactions between PRP8 and PRP17/CDC40, two yeast genes involved in pre-mRNA splicing and cell cycle progression. Genetics. 2000;154:61-71.
24. Ben Yehuda S, Dix I, Russell CS, Levy S, Beggs JD, Kupiec M. Identification and functional analysis of hPRP17, the human homologue of the PRP17/CDC40 yeast gene involved in splicing and cell cycle control. RNA. 1998;4:1304-12.
25. Wan HY, Li QQ, Zhang Y, Tian W, Li YN, Liu M, Li X, Tang H. MiR-124 represses vasculogenic mimicry and cell motility by targeting amotL1 in cervical cancer cells. Cancer Lett. 2014;355:148-58.
26. Doitsh G, Shaul Y. Enhancer I predominance in hepatitis B virus gene expression. Mol Cell Biol. 2004;24:1799-808.
27. Kim SY, Kim JC, Kim JK, Kim HJ, Lee HM, Choi MS, Maeng PJ, Ahn JK. Hepatitis B virus X protein enhances NFkappaB activity through cooperating with VBP1. BMB Rep. 2008;41:158-63.
28. Schottelius AJ, Dinter H. Cytokines, NF-kappaB, microenvironment, intestinal inflammation and cancer. Cancer Treat Res. 2006;130:67-87.
29. Sapra AK, Arava Y, Khandelia P, Vijayraghavan U. Genome-wide analysis of pre-mRNA splicing: intron features govern the requirement for the second-step factor, Prp17 in Saccharomyces cerevisiae and Schizosaccharomyces pombe. J Biol Chem. 2004;279:52437-46.
30. Chawla G, Sapra AK, Surana U, Vijayraghavan U. Dependence of pre-mRNA introns on PRP17, a non-essential splicing factor: implications for efficient progression through cell cycle transitions. Nucleic Acids Res. 2003;31:2333-43.
31. Kaplan Y, Kupiec M. A role for the yeast cell cycle/splicing factor Cdc40 in the G1/S transition. Curr Genet. 2007;51:123-40.
32. Wang KY, Ma J, Zhang FX, Yu MJ, Xue JS, Zhao JS. MicroRNA-378 inhibits cell growth and enhances L-OHP-induced apoptosis in human colorectal cancer. IUBMB Life. 2014;66:645-54.
33. van Zijl F, Mall S, Machat G, Pirker C, Zeillinger R, Weinhaeusel A, Bilban M, Berger W, Mikulits W. A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression. Mol Cancer Ther. 2011;10:850-60.